Metrohm and FOSS Enter Strategic Alliance
Metrohm and FOSS have entered into a strategic alliance in which Metrohm will become the sole global distributor of FOSS NIR instruments for the pharmaceutical sector.
Metrohm and FOSS have entered into a strategic alliance in which Metrohm will become the sole global distributor of FOSS NIR instruments for the chemical, petrochemical, pharmaceutical, and environmental sectors.
“Metrohm will extend its product offering beyond the company’s traditional focus on solutions for wet-chemistry analytical techniques thereby benefiting our customers with new possibilities both in laboratory and process analysis,” said Christoph Fässler, CEO of Metrohm in a company statement.
FOSS will continue its R&D program within NIR technology and manufacturing for both companies and will focus its NIR business on the food and agricultural industries, according to a joint company statement.
Under the deal, FOSS NIRSystems, Inc., based in Laurel, MD, USA, will become a division of Metrohm USA to be named Metrohm NIRSystems. The global NIR instrument business for these sectors will continue to be run by the Metrohm NIRSystems division of Metrohm USA.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.
